Rachel’s note: Before today’s Dispatch, I wanted to remind you about our colleague Jeff Brown’s urgent masterclass tonight at 8 p.m. ET.

Jeff’s considered by many to be America’s #1 tech advisor. And he’s agreed to go on camera and reveal all the details behind the top biotech company on his buy list.

It’s a unique opportunity to look over Jeff’s shoulder… and learn how a small stake today could impact you and your loved ones for generations to come…

Go here to RSVP for free. Then, read on below for why COVID-19 has caused a “boom” in stocks… and how you can reap the rewards…

By Jeff Brown, editor, The Bleeding Edge

Jeff Brown

I remember it to this day…

It was June 2015.

A little-known financial asset was gaining the attention of a niche group of investors.

It promised independent financial transactions without the need for a “trusted” third party. It was being compared to gold and silver but was infinitely more transportable.

But even more interesting, the asset had just come off an incredible run, climbing more than 600% in just a few months of 2013.

I’m referring, of course, to bitcoin.

At the time, bitcoin was not well understood. It certainly was not yet plastered all over Bloomberg and CNBC.

So in June 2015, I published a write-up on bitcoin. I titled it “What’s the Big Deal With Bitcoin?”

In that editorial, I explained how bitcoin operated, how blockchain technology supported it, and why it was progressing so quickly. I even encouraged interested readers to “dip their toes” into cryptocurrency and buy a few bitcoins.

At the time, the cryptocurrency was trading for about $250. Buying several bitcoins would have been manageable.

We all know what happened next…

Starting in June 2015, bitcoin climbed almost 7,900%, hitting nearly $20,000 in late 2017. Even after the pullback in early 2018, bitcoin is still trading over 8,000% above its June 2015 levels at writing.

Investors who listened to me all those years ago made an outstanding return in the span of just a few years.

I mention this story because I believe we are gearing up for a bull market that will rival bitcoin’s in 2017.

But this bull market has absolutely nothing to do with cryptocurrencies.

Instead, it’s happening in a technology sector that is heading into overdrive…

A Golden Age of Technology

The technology trend I’m referring to is called precision medicine. This is an emerging approach to treat and prevent diseases by considering each person’s genetic makeup, environment, and lifestyle.

This isn’t just another drug or treatment… precision medicine offers a whole new way of thinking about health care.

And we’re going to be investing in the companies fueling this trend.

Medicine is nothing like it was 20 years ago. It is moving much faster now. And the field of biotechnology encompasses a much larger range of technologies than it used to.

There has been a dramatic increase in computer processing power over the last 20 years.

At the same time, we’ve seen exponentially lower costs of “renting” powerful computers and computer storage because of companies like Amazon Web Services (AWS).

And when you include powerful artificial intelligence and machine learning software, innovation is happening at a pace that was unforeseen even just a few years ago.

And it is not just about developing individual therapies. These companies are building technology platforms to aid in drug discovery. They are using semiconductor technology to accelerate the analysis of proteins and enzymes.

At the same time, there has been an explosion in genetic data from human DNA. And we can now apply artificial intelligence to help us understand the complex relationship between our genetic material and disease.

All of this would be reason enough to take an interest in the precision medicine trend. But earlier this year, something unexpected happened: the COVID-19 pandemic.

And it changed the course of this technology forever.

COVID-19 Tech Boom

It may sound strange to say that COVID-19 has caused a “boom” in stocks. After all, the virus was chiefly responsible for the fear-induced selling we saw back in March.

But when it comes to this technology, that’s precisely what’s happened. Because of COVID-19, the world has woken up to how powerful modern biotech can be.

Consider just one example…

Back in March, an early stage company AbCellera did something that many people thought was impossible.

AbCellera received a blood sample from a patient who had recovered from COVID-19. The company used artificial intelligence (AI) to screen more than five million immune cells in that sample. And it identified about 500 antibodies that helped the patient fight off the virus.

Identifying these antibodies could be the key to treating COVID-19. AbCellera used this as a starting point to create an antibody therapy to potentially cure COVID-19.

Historically, this process would have taken years to accomplish. So how long did it take AbCellera? Just 11 days. Beyond incredible.

And the industry took notice…

Pharmaceutical giant Eli Lilly rushed to partner with AbCellera. They worked on a treatment using these antibodies.

And in June, AbCellera sent its COVID-19 antibody therapy to clinical trials. It was the first company to do so.

Then, on November 10, the Food and Drug Administration (FDA) issued an emergency use authorization for its antibody treatment.

Make no mistake, this is revolutionary work.

Until just recently, this entire process would have taken years. But AbCellera pulled it off in just months.

In all my years as an analyst, I’ve never seen this type of speed from the health care industry. And it’s thanks in large part to COVID-19. The virus has lit a fire under this trend.

And the venture capital (VC) community is starting to notice…

A Tsunami of VC Funding

Have a look at this chart.

This chart tracks the amount of venture capital flowing into the biotechnology industry.

A stunning $34.6 billion has been invested into private biotech companies so far this year, a 327% increase over 2010.

And that’s just the start…

Biotechnology initial public offerings (IPOs) have raised roughly $23 billion for drug development this year.

That’s an incredible amount of capital flowing into the space.

Why is this happening?

Private capital sees what I see. The precision medicine trend is gearing up for a massive run in the years ahead. And this “smart money” is taking its position now.

How to Profit From the Boom

Back in 2015, I’m sure plenty of readers were skeptical when I recommended buying a modest amount of bitcoin. I’m sure several readers ignored that advice. And I’m certain they regret it now.

If you missed the boat on bitcoin in 2015, then pay close attention.

I believe the level of awareness for precision medicine among investors will rival that of the cryptocurrency boom in 2017.

We’re going to be curing diseases, not just treating the symptoms… discovering problems before we get sick… and developing personalized therapies when we do get sick rather than relying on the “one size fits all” methods we have been using. And we’ll be doing all this faster than we’ve ever been able to before.

And as a result, the returns we will see from quality tech companies will create lasting, generational wealth.

For investors, the time to get exposure to these stocks is now. Right now.

That’s why I’m hosting a free special presentation, The Cure Event, tonight at 8 p.m. ET.

During this event, I’ll tell you all about a little-known stock with blockbuster potential. I believe this stock could soar up to 1,000% in as little as one day.

You don’t want to miss out. Go right here to RSVP for my event tonight.

I hope to see you there.


Jeff Brown
Editor, The Bleeding Edge